Search results
Results from the WOW.Com Content Network
The biotech industry has lagged the broader market so far in 2024. The SPDR S&P Biotech ETF, an industry benchmark, is up 9% this year compared to 28% for the S&P 500. Will that trend continue in ...
Although no clinical development took place, Axovant held its IPO in June 2015 and raised $315 million, [4] the largest biotech IPO ever, [9] based on new phase IIB trials that were more promising. [10] The lock-up period against reselling stock was reduced to an unusually short 90 days for hedge funds that showed interest in the IPO. [11]
The IPO was initially priced at 27€ per share, [14] [15] and a potential valuation of up to 4.1 billion euros, [16] but increased the share price to 30€ the following day. [17] [13] The IPO was the largest of the year in Germany. [18] [19] In December 2023, Schott Pharma was included in the SDAX. [20]
Kadmon Corporation (originally Kadmon Pharmaceuticals) is a biopharmaceutical company based in New York City.It also has operations in Warrendale, PA and Brighton, MA.The company was founded in 2009 by Samuel D. Waksal, [2] [3] founder and former CEO of ImClone Systems, a company now fully merged into Eli Lilly.
Kioxia's filings indicate it aims to conduct the IPO sometime from December through June. A Bain-led consortium acquired Kioxia from scandal-hit Toshiba six years ago for 2 trillion yen.
Some 108 companies conducted their IPO in 2023 and raised $19.4 billion, according to Renaissance Capital. Those figures rose markedly from the 2022 doldrums of 71 IPOs and just $7.7 billion raised.
In December 2014, Kite Pharma sold 4,007,750 shares of it common stock in their follow-on offering at $54.00 per share, for gross proceeds of $216.4 million. [49] In March 2015, Kite Pharma acquired T-Cell Factory (TCF), a privately held biotechnology company based in the Netherlands, for €20 million and renamed it – Kite Pharma EU.
Science & Tech. Shopping. Sports